Aarti Drugs Reports Strong Financial Growth in May 2025 Results

Aarti Drugs, a small-cap player in the Pharmaceuticals & Drugs industry, has recently reported its financial results for the quarter ending March 2025. The results, declared on May 6, 2025, indicate a notable shift in the company's financial evaluation. The score has seen an adjustment, moving to a new level from the previous assessment. The financial data reveals several positive trends for Aarti Drugs. The operating profit to interest ratio has reached its highest point in the last five quarters, indicating an enhanced capacity to manage interest obligations. Additionally, the profit before tax, excluding other income, has shown significant growth, reaching Rs 69.29 crore, which is a marked increase compared to the average of the previous four quarters. Similarly, the profit after tax has also demonstrated substantial growth, now standing at Rs 62.86 crore. Net sales have peaked at Rs 676.76 crore, marking the highest figure in the last five quarters, while operating profit has also reached a new high of Rs 93.33 crore. Furthermore, earnings per share have improved, reflecting the company's ability to generate higher returns for its shareholders. Overall, Aarti Drugs is experiencing a positive financial trajectory, as evidenced by the recent results. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.